-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 PLx8IC9EZR4mrRu+nU5rGwN7AK9UrPzcMlZI/9cgAH3kehGhc6Sh/6mdZcQiyWGY
 /CJcUQQnYX4EHVYkBu2gtg==

<SEC-DOCUMENT>0000950123-10-098160.txt : 20101029
<SEC-HEADER>0000950123-10-098160.hdr.sgml : 20101029
<ACCEPTANCE-DATETIME>20101029161226
ACCESSION NUMBER:		0000950123-10-098160
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20101025
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101029
DATE AS OF CHANGE:		20101029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS BIOTECHNOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		101152040

	BUSINESS ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205
		BUSINESS PHONE:		410-369-0365

	MAIL ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c07441e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="margin-left: 0.25in; width: 7.5in;font-family: 'Times New Roman',Times,serif">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 OR 15(d) of The Securities Exchange Act of 1934</B>
</DIV>

<!-- xbrl,dc -->
<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): October 25, 2010</B></DIV>
<!-- /xbrl,dc -->
<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>CHAMPIONS BIOTECHNOLOGY, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD nowrap align="center" valign="top"><B>Delaware
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>0-17263
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>52-1401755</B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Commission File Number)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(IRS Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="48%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD align="center" valign="top"><B>Science and Technology Park at Johns Hopkins<BR>
855 N. Wolfe Street, Suite 619, Baltimore,
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="bottom"><B>MD 21205&nbsp;<BR></B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(Address of principal executive offices)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code: <B>(410) 369-0365</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Inapplicable</B></DIV>

<DIV align="center" style="font-size: 10pt"><FONT style="border-top: 1px solid #000000">(Former name or former address, if changed since last report.)</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio --> </DIV>











<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>








<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>INFORMATION TO BE INCLUDED IN THE REPORT</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;1.01. Entry into a Material Definitive Agreement.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The information required by this Item is described in Item&nbsp;5.02(c) and (d)&nbsp;below.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;3.02. Unregistered Sales of Equity Securities.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The information required by this Item is described in Item&nbsp;5.02 below.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B>(c)&nbsp;(d) </B>On October&nbsp;25, 2010, the Board of Directors (the &#147;<B>Board</B>&#148;) of Champions Biotechnology,
Inc. (the &#147;<B>Company</B>&#148;) appointed Joel Ackerman, age 45, as Chief Executive Officer of the Company
effective October&nbsp;26, 2010 (the &#147;<B>Commencement Date</B>&#148;) pursuant to the terms of an employment
agreement dated October&nbsp;25, 2010. As Chief Executive Officer, Mr.&nbsp;Ackerman, together the Company&#146;s
President, would be responsible for implementing the Company&#146;s strategy, and would be primarily
responsible for finance, administration and general corporate matters and operations of the drug
development business.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under the terms of the agreement, Mr.&nbsp;Ackerman will also be appointed as a member of the
Board. Mr.&nbsp;Ackerman will receive options to purchase 2,500,000 shares of the Company&#146;s Common
Stock at an exercise price of $0.875 per share, which vest and become exercisable in 36 equal
monthly installments beginning on the Commencement Date. Mr.&nbsp;Ackerman will also receive options to
purchase an additional 2,500,000 shares of the Company&#146;s Common Stock at an exercise price of
$0.875 per share, which vest in 36 equal monthly installments beginning on the Commencement Date,
but are only exercisable upon the Company meeting all of certain milestones during the three year
period following the Commencement Date. All options will be granted under the Company&#146;s 2010
Equity Incentive Plan (described below). All unvested options vest immediately upon a change of
control of the Company or the termination of Mr.&nbsp;Ackerman without cause. All unexercised options
will lapse and be canceled 90&nbsp;days following the termination of Mr.&nbsp;Ackerman with cause or the
resignation of Mr.&nbsp;Ackerman from the Company.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Board believes that Mr.&nbsp;Ackerman&#146;s background and vast business experience make him
uniquely qualified to serve as Chief Executive Officer and as a member of the Board. Mr.&nbsp;Ackerman
received a Bachelor of Arts degree summa cum laude from Columbia University in 1988 and a Masters
degree in physics from Harvard University in 1990. From 1990 to 1993, Mr.&nbsp;Ackerman was an
associate with Mercer Management Consulting, a global strategy consulting firm offering in-depth
advice to Fortune 1000 companies in a broad range of industries. From 1993 to 2008, Mr.&nbsp;Ackerman
was employed by Warburg Pincus LLC, which since 1971 has invested more than $31&nbsp;billion in
approximately 600 companies in 30 countries and across a range of sectors, including healthcare,
financial services, industrial, technology, media and telecommunications, energy, consumer and
retail and real estate, including $6.6&nbsp;billion invested in healthcare-related companies around the
world. At Warburg Pincus, Mr.&nbsp;Ackerman served in various capacities including managing director
and head of the firm&#146;s healthcare services group and a member of the firm&#146;s executive management
team. During his nine years as head of Warburg Pincus&#146; healthcare services group, Mr.&nbsp;Ackerman was
responsible for setting annual strategic priorities, allocating resources among the group&#146;s
sub-sectors, generating deal flow, triaging investment opportunities, performing due diligence and
negotiating transactions, arranging and structuring financing, presenting investments to investment
committee, monitoring investments and exiting investments. In addition, Mr.&nbsp;Ackerman represented
Warburg Pincus as a member of the boards of directors of numerous portfolio companies. Since 2009,
Mr.&nbsp;Ackerman has been a senior portfolio fellow with Acumen Fund, a non-profit global venture fund
that uses entrepreneurial approaches to address global poverty.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Mr.&nbsp;Ackerman is a member of the board of directors of Coventry Health Care, Inc., a publicly
traded managed care company, and of Kindred Healthcare, Inc., a publicly traded company that
operates hospitals and nursing homes.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On October&nbsp;25, 2010, the Board appointed Ronnie Morris, M.D., age 44, as President of the
Company effective the Commencement Date pursuant to the terms of an employment agreement dated
October&nbsp;26, 2010. As President, Dr.&nbsp;Morris, together the Company&#146;s Chief Executive Officer, would
be responsible for implementing the Company&#146;s strategy, and would be primarily responsible for
personalized oncology services and all aspects of the Company&#146;s medical and scientific activities.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under the terms of the agreement, Dr.&nbsp;Morris will be appointed as a member of the Board and
will be employed and serve as president of a newly formed Israeli subsidiary of the Company at an
annual salary of NIS 46,200 (approximately $12,800). In addition, Dr.&nbsp;Morris will receive options
to purchase 2,500,000 shares of the Company&#146;s Common Stock at an exercise price of $0.875 per
share, which vest and become exercisable in 36 equal monthly installments beginning on the
Commencement Date. Dr.&nbsp;Morris will also receive options to purchase an additional 2,500,000 shares
of the Company&#146;s Common Stock at an exercise price of $0.875 per share, which vest in 36 equal
monthly installments beginning on the Commencement Date, but are only exercisable upon the Company
meeting all of certain milestones during the three year period following the Commencement Date.
All options will be granted under the Company&#146;s 2010 Equity Incentive Plan (described below). All
unvested options vest immediately upon a change of control of the Company or the termination of Dr.
Morris without cause. All unexercised options will lapse and be canceled 90&nbsp;days following the
termination of Dr.&nbsp;Morris with cause or the resignation of Dr.&nbsp;Morris from the Company.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Board believes that as President of the Company and a member of the Board, Dr.&nbsp;Morris will
bring his background and medical and business experience to bear on the Company&#146;s personalized
oncology services to grow the Company&#146;s market and profitability. Dr.&nbsp;Morris received his medical
degree from the University of Medicine and Dentistry of New Jersey in 1993, completed his residency
at the Long Island Jewish Medical Center in 1996, and has Board certification by the American Board
of Internal Medicine in 1996. From 1996 to 2001, Dr.&nbsp;Morris practiced internal medicine and was a
managing partner of Prohealth Medical Group in Boca Raton Florida where, in addition to his
personal medical practice of more than 2,500 patients, he managed over 30 physicians in a
multispecialty practice, was responsible for the practice&#146;s financial operations, and coordinated
and created ancillary revenue services for the practice. From 2004 to 2006, Dr.&nbsp;Morris was vice
president and medical director of AllianceCare Inc. in Boynton Beach, Florida, a company that
provided home health care, physical therapy and doctor &#147;house calls&#148;. In that capacity, Dr.&nbsp;Morris
was responsible for the physician house call business, developed new markets, managed and directed
150 employees, tripled revenue and brought his division to profitability. In 2001, Dr.&nbsp;Morris
co-founded MDVIP, Inc. in Boca Raton, Florida, a personalized healthcare services company. Until
2009 when MDVIP was acquired by Procter and Gamble Co., Dr.&nbsp;Morris served on MDVIP&#146;s board of
directors, as medical director, and as a member of its executive management team. In those
capacities, Dr.&nbsp;Morris conceptualized, developed, and helped build MDVIP from a start-up company
into a national leader in personalized healthcare services with a network of 400 doctors in 29
states and 125,000 consumers/patients. From 2009 to the present, Dr.&nbsp;Morris has been a private
investor.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B>(e)&nbsp;</B>On October&nbsp;25, 2010, the Board adopted the Company&#146;s 2010 Equity Incentive Plan (the &#147;<B>2010
Plan</B>&#148;), subject to approval by the Company&#146;s shareholders, to provide equity-based incentive awards
to the Company&#146;s and its subsidiaries&#146; employees, directors and consultants, thereby continuing to
align the interests of such individuals with those of the shareholders. The Company will reserve
30,000,000 shares of the Company&#146;s Common Stock for issuance under the 2010 Plan.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The 2010 Plan will be administered by the Compensation Committee of the Company&#146;s Board of
Directors (the &#147;<B>Committee</B>&#148;). The Committee has the authority, within limitations as set forth in
the 2010 Plan, to interpret the terms of the 2010 Plan and establish rules and regulations
concerning the 2010 Plan, to determine the persons to whom options may be granted, the number of
Shares to be covered by each option, and the exercise price and other terms and provisions of the
option to be granted. In addition, the Committee has the
authority, subject to the terms of the 2010 Plan, to determine the appropriate adjustments in the
terms of each outstanding option in the event of a change in the Company&#146;s capital structure.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Options granted under the 2010 Plan may be either incentive stock options (&#147;<B>ISOs</B>&#148;) within the
meaning of Section&nbsp;422 of the Internal Revenue Code, non-qualified stock options (&#147;<B>NQSOs</B>&#148;),
Restricted Stock Awards (&#147;<B>RSAs</B>&#148;) or Stock Appreciation Rights (&#147;<B>SARs</B>&#148;) as the Options Committee may
determine. The exercise price of an option will be fixed by the Committee on the date of grant,
except that (i)&nbsp;the exercise price of an ISO granted to any employee who owns (directly or by
attribution) shares possessing more than 10% of the total combined voting power of all classes of
outstanding stock of the Company (a &#147;<B>10% Owner</B>&#148;) must be at least equal to 110% of the fair market
value of the shares on the date of grant, (ii)&nbsp;the exercise price of an ISO granted to any
employee other than a 10% Owner must be at least equal to the fair market value of the shares on
the date of the grant, (iii)&nbsp;the exercise price of any stock option shall not be less than one
hundred percent (100%) of the fair market value of the Shares subject to the option on the date the
option is granted. Any options granted must expire within ten years from the date of grant (five
years in the case of an ISO granted to a 10% Owner). Shares subject to options granted under the
2010 Plan which expires, terminate, or are canceled without having been exercised in full become
available again for option grants. At the time of the grant of a RSA, the Board will determine the
price to be paid by the participant for each share subject to the RSA. To the extent required by
applicable law, the price to be paid by the participant for each share of the RSA will not be less
than the par value per Share. A RSA may be awarded as a stock bonus (<I>i.e.</I>, with no cash purchase
price to be paid) to the extent permissible under applicable law. SAR agreements will be in such
form and will contain such terms and conditions as the Board deems appropriate. The strike price
of each SAR will not be less than the fair market value of the share equivalents on the date of
grant. Any SAR granted must expire within ten years from the date of grant.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>(d)&nbsp;Exhibits</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The following exhibits are filed herewith:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="justify" style="border-bottom: 1px solid #000000">Exhibit No.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="justify" valign="top">Employment Agreement dated October&nbsp;25, 2010 between the Company and Joel Ackerman</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.2.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="justify" valign="top">Employment Agreement dated October&nbsp;25, 2010 between the Company and Ronnie Morris, M.D.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="justify" valign="top">Press release dated October&nbsp;28, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="justify">&nbsp;</TD>
    <TD colspan="3" align="justify"><B>CHAMPIONS BIOTECHNOLOGY, INC.</B><BR>
(Registrant)<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="justify">Date: October 29, 2010&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="justify">/s/ Mark Schonau
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="justify">Mark Schonau&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="justify">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>c07441exv10w1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><U><B>Exhibit&nbsp;10.1</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">CHAMPIONS BIOTECHNOLOGY, INC.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt">October&nbsp;25, 2010
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Joel Ackerman
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dear Mr.&nbsp;Ackerman:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We are pleased to offer you employment as the Chief Executive Officer of Champions Biotechnology,
Inc. (the &#147;Company&#148;). For so long as you serve as an executive officer of the Company, the Company
will nominate you as a member of the board of directors of the Company. This offer is contingent
upon your signing our Business Protection Agreement, a copy of which is attached hereto, which
protects the Company&#146;s intellectual property and good will, among other things. You will be
entitled to indemnification by the Company to the fullest extent permitted by law pursuant to the
Indemnification Agreement attached hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">You will not be entitled to receive any salary or compensation other than the Options described
below, will not be entitled to any severance payments and you have elected to waive any employee
benefits. Upon the Commencement Date (as defined) below, you will be entitled to receive options
to purchase 5,000,000 shares of common stock of the Company on the terms set forth in <U>Schedule&nbsp;A</U> attached hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Upon the closing of the next round of financing of the Company in the aggregate amount of at least
$5,000,000, and on the same price and other terms thereof, you will invest in the Company between
$250,000 and $500,000 (the &#147;Personal Investment&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our employment relationship will not be for any specified duration and it will be terminable at
will, which means that either you or the Company may terminate it at any time. To facilitate the
Company&#146;s provision of quality service, we expect you to provide at least 30&nbsp;days&#146; advance written
notice if you decide to resign. If you decide to resign, you agree to resign also from the board
of directors of the Company and any subsidiary thereof. Any dispute regarding your employment will
be governed solely by the laws of the State of Maryland. You and the Company agree that any
action arising out of your employment will be brought in and will be subject to the exclusive
jurisdiction and venue of the state courts located in Baltimore, Maryland or the Federal District
Court for the Northern District of Maryland.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">This letter (including Schedule&nbsp;A attached hereto) contains the entire agreement between you and
the Company and supersedes any prior or agreement, understanding or commitment (oral or written) by
or on behalf of the Company, except for the Business Protection Agreement and the Indemnification
Agreement. The terms of your employment may be amended in the future, but only in writing and
signed by both you and by an authorized officer of the Company.
We expect that your engagement with us would start on October&nbsp;26, 2010, or another mutually
satisfactory date (such start date, the &#147;Commencement Date&#148;). Within 30&nbsp;days after the
Commencement Date, we will adopt a new stock option plan (the &#147;ISO Plan&#148;) and present it for
shareholder approval as soon as practicable thereafter to enable your stock options to be treated
as incentive stock options for purposes of U.S. federal tax law, to the fullest extent permitted
under applicable law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We believe you will be a productive member of our team and we hope you will accept our offer. If
you wish to do so, please sign this letter and return it to the Company within 10&nbsp;days after the
date of this letter. We look forward to your joining our Company.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Champions, Biotechnology, Inc.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark Schonau, CFO
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>

    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>

    <TD colspan="3" align="left">Agreed and accepted:<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="left">&nbsp;</TD>
</TR><TR>

    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Joel Ackerman
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>

    <TD colspan="3" align="left">Employee Signature&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>

    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Date: October&nbsp;25, 2010

</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><U>Schedule&nbsp;A to Agreement with Joel Ackerman</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><U>Option Terms</U>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Number of Options Shares: 5,000,000.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Option Term: 10&nbsp;years.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Exercise Price: The market price of the Company&#146;s common stock, which is $0.875 per
share. Cashless exercise shall be permitted at your election starting two years after the
Commencement Date.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Vesting Schedule:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>2,500,000 options (the &#147;Non-contingent Options&#148;) shall vest monthly over
three years, in 36 equal installments, commencing from the Commencement Date.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>2,500,000 options (the &#147;Contingent Options&#148;) shall vest monthly over
three years, in 36 equal installments, commencing from the Commencement Date but
subject also to satisfaction of the following conditions during the option term (the
&#147;Conditions&#148;):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Closing of one or more financings of the Company in the
aggregate amount of at least $5,000,000 (including your Personal Investment
and that of Dr.&nbsp;Ronnie Morris).</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bringing in new Company management.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Launching of personalized medicine (oncology)&nbsp;business.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Commencing implementation of Business Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon satisfaction of all of the Conditions, all Contingent Options that
would have vested had the vesting commenced from the Commencement Date shall
vest immediately. By way of illustration, if the conditions are satisfied
nine months following the Commencement Date, 9/36ths, or 25% of the
Contingent Options, shall vest.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>So long as the Conditions are not satisfied, the Contingent Options shall
not be exercisable; if all of the Conditions are not satisfied within the
three year vesting period, the Contingent Options shall lapse and terminate.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At your request from time to time, the Company shall confirm whether any
of the Conditions has been satisfied, as determined in good faith by its
Board of Directors.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Notwithstanding the foregoing, all options vest and become fully
exercisable upon a &#147;Change of Control&#148; (as defined below) or termination of
employment without &#147;Cause&#148; (as defined below).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Non-Contingent Options will expire 90&nbsp;days following termination for Cause or
voluntary resignation; the Contingent Options will not be affected by such events, except
that vesting shall cease.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Grant Date: The options shall be granted upon adoption of the ISO Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tax Treatment: The options will be incentive stock options, to the fullest extent
permitted under applicable law.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Transferability: The options will be transferable by you to trusts of which you or your
family members are beneficiaries to the extent permitted by law.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It is understood that at the present time, in view of the Company&#146;s plans for raising
capital, the Company may not have sufficient authorized but unissued shares of common stock
necessary upon the exercise of the Options. The Company will take such action as may be
reasonable and practical, as promptly as practicable and in any event within 90&nbsp;days of the
Commencement Date, to increase the number of authorized but unissued shares of common stock
to provide for the shares needed to be issued upon the exercise of the Options (the
&#147;Capital Increase&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All shares underlying the options will be registered by the Company with the Securities
and Exchange Commission on Form S-8 within 15&nbsp;days following the effective date of the
Capital Increase.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">For purposes of this agreement, the following capitalized terms that have the following respective
meanings:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#147;Cause&#148; shall mean any of the following: (i)&nbsp;willful misconduct in the performance of your material
duties; (ii)&nbsp;participation in any fraud against the Company; (iii)&nbsp;conviction of, or a plea of
&#147;guilty&#148; or &#147;no contest&#148; to, a felony or any crime involving dishonesty; or (iv)&nbsp;intentional damage
to any property of the Company of material value.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#147;Change of Control&#148; shall mean the occurrence of any of the following:
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(a)&nbsp;any &#147;person,&#148; as such term is currently used in Section 13(d) of the Securities Exchange Act of
1934, as amended (the &#147;1934 Act&#148;) (a &#147;person&#148;), other than Dr.&nbsp;David Sidransky, becomes a
&#147;beneficial owner&#148; (as such term is currently used in
Rule&nbsp;13d-3 promulgated under the 1934 Act (a &#147;Beneficial Owner&#148;) of 30% or more of the Voting Stock
(as defined below) of the Company;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(b)&nbsp;the Board of Directors of the Company adopts any plan of liquidation providing for the
distribution of all or substantially all of the Company&#146;s assets;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(c)&nbsp;all or substantially all of the assets or business of the Company are disposed of in any one or
more transactions pursuant to a sale, merger, consolidation or other transaction (unless the
shareholders of the Company immediately prior to such sale, merger, consolidation or other
transaction beneficially own, directly or indirectly, in substantially the same proportion as they
owned the Voting Stock of the Company, more than fifty percent (50%) of the Voting Stock or other
ownership interests of the entity or entities, if any, that succeed to the business of the
Company);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(d)&nbsp;the Company combines with another company and is the surviving corporation but, immediately
after the combination, the shareholders of the Company immediately prior to the combination hold,
directly or indirectly, fifty percent (50%) or less of the Voting Stock of the combined company; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(e)&nbsp;Continuing Directors cease to constitute at least a majority of the Board of Directors of the
Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#147;Voting Stock&#148; of any entity shall mean the issued and outstanding share capital or other
securities of any class or classes having general voting power under ordinary circumstances, in the
absence of contingencies, to elect the members of the board of directors (or members of a similar
managerial body if such entity has no board of directors) of such entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#147;Continuing Director&#148; means a director who either was a director of the Company on the Commencement
Date or who became a director of the Company subsequent thereto and whose election, or nomination
for election by the Company&#146;s shareholders, was approved by a majority of the Continuing Directors
then on the Board of Directors of the Company.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>c07441exv10w2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><U><B>Exhibit&nbsp;10.2</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">CHAMPIONS BIOTECHNOLOGY, INC.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt">October&nbsp;25, 2010
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Ronnie Morris, M.D.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dear Dr.&nbsp;Morris:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We are pleased to offer you the position of President of Champions Biotechnology, Inc. (the
&#147;Company&#148;). You will be employed by, and also serve as President of, the subsidiary of the Company
that is currently being formed in Israel. For so long as you serve as an executive officer of the
Company, the Company will nominate you as a member of the board of directors of the Company. This
offer is contingent upon your signing our Business Protection Agreement, a copy of which is
attached hereto, which protects the Company&#146;s intellectual property and good will, among other
things. You will be entitled to indemnification by the Company to the fullest extent permitted by
law pursuant to the Indemnification Agreement attached hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">You will be entitled to salary equal to the minimum wage in Israel, as may be in effect from time
to time, which is currently NIS 3,850 per month. You will not be entitled to receive severance
payments or to receive employee benefits, except as required by applicable Israeli labor law. You
will be entitled to receive options to purchase 5,000,000 shares of common stock of the Company at
the times and on the terms set forth in <U>Schedule&nbsp;A</U> attached hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Upon the closing of the next round of financing of the Company in the aggregate amount of at least
$5,000,000, and on the same price and other terms thereof, you will invest in the Company between
$250,000 and $500,000 (the &#147;Personal Investment&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our employment relationship will not be for any specified duration and it will be terminable at
will, which means that either you or the Company may terminate it at any time. To facilitate the
Company&#146;s provision of quality service, we expect you to provide at least 30&nbsp;days&#146; advance written
notice if you decide to resign. If you decide to resign , you agree to resign also from the board
of directors of the Company and any subsidiary thereof. Any dispute regarding your employment will
be governed solely by the laws of Israel. You and the Company agree that any action arising out
of your employment will be brought in and will be subject to the exclusive jurisdiction and venue
of the competent courts in Israel.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">This letter (including Schedule&nbsp;A attached hereto) contains the entire agreement between you and
the Company and supersedes any prior or agreement, understanding or commitment (oral or written) by
or on behalf of the Company, except for the Business Protection Agreement and the Indemnification
Agreement. The terms of your employment may be amended in the future, but only in writing and
signed by both you and by an authorized officer of the Company.
We expect that your engagement with us would start on October&nbsp;26, 2010, or another mutually
satisfactory date (such start date, the &#147;Commencement Date&#148;). We will form the Israeli subsidiary
that will employ you as soon as practicable and in no event later than November&nbsp;30, 2010. We will
cause the Israeli subsidiary to adopt a stock option plan in form and substance satisfactory to you
and retain a trustee under Section&nbsp;102 of the Israeli Tax Ordinance &#091;New Version&#093;, 1961 (&#147;Israeli
Section&nbsp;102&#148;) and file said plan with the Israel Tax Authority as soon as practicable after its
formation and in no event later than November&nbsp;30, 2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We believe you will be a productive member of our team and we hope you will accept our offer. If
you wish to do so, please sign this letter and return it to the Company within 10&nbsp;days after the
date of this letter. We look forward to your joining our Company.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Champions, Biotechnology, Inc.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark Schonau, CFO
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>

    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>

    <TD colspan="3" align="left">Agreed and accepted:<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="left">&nbsp;</TD>
</TR><TR>

    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Ronnie Morris
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>

    <TD colspan="3" align="left">Employee Signature&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>

    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Date: October&nbsp;25, 2010

</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><U>Schedule&nbsp;A to Agreement with Dr.&nbsp;Ronnie Morris</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><U>Option Terms</U>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Number of Options Shares: 5,000,000, which will be granted to Dr.&nbsp;Ronnie Morris
pursuant to Israeli Section&nbsp;102 (the &#147;Personal Options&#148;), provided, however, that at the
election of Dr.&nbsp;Morris, up to 1,500,000 of such options will be granted to the R A Morris
Family Foundation (the &#147;Foundation Options&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Option Term: 10&nbsp;years.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Exercise Price: The market price of the Company&#146;s common stock, which is $0.875 per
share. Cashless exercise shall be permitted at your election starting two years after the
Commencement Date.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Vesting Schedule:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>2,500,000 options (i.e., half the Personal Options and half the
Foundation Options, if any) (the &#147;Non-contingent Options&#148;) shall vest monthly over
three years, in 36 equal installments, commencing from the Commencement Date.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>2,500,000 options (i.e., half the Personal Options and half the
Foundation Options, if any) (the &#147;Contingent Options&#148;) shall vest monthly over three
years, in 36 equal installments, commencing from the Commencement Date but subject
also to satisfaction of the following conditions during the option term(the
&#147;Conditions&#148;):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Closing of one or more financings of the Company in the
aggregate amount of at least $5,000,000 (including your Personal Investment
and that of Joel Ackerman).</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bringing in new Company management.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Launching of personalized medicine (oncology)&nbsp;business.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Commencing implementation of Business Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon satisfaction of all of the Conditions, all Contingent Options that
would have vested had the vesting commenced from the Commencement Date shall
vest immediately. By way of illustration, if the conditions are satisfied
nine months following the Commencement Date, 9/36ths, or 25% of the
Contingent Options, shall vest.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>So long as the Conditions are not satisfied, the Contingent Options shall
not be granted or exercisable; if all of the Conditions are not satisfied
within the three year vesting period, the Contingent Options shall lapse and
terminate.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At your request from time to time, the Company shall confirm whether any
of the Conditions has been satisfied, as determined in good faith by its
Board of Directors.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Notwithstanding the foregoing, all options vest and become fully
exercisable upon a &#147;Change of Control&#148; (as defined below) or termination of
employment without &#147;Cause&#148; (as defined below).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Non-Contingent Options will expire 90&nbsp;days following termination for Cause or
voluntary resignation; the Contingent Options will not be affected by such events, except
that vesting shall cease.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Grant Date: All of the Non-contingent Options and 2,250,000 of the Contingent Options
shall be granted on the 31<SUP style="FONT-size: 85%; vertical-align: text-top">st</SUP> day following the filing of the option plan with
the Israel Tax Authority. The balance of 250,000 Contingent Options shall be granted
immediately upon the satisfaction of the Conditions, on the same terms as the
Non-Contingent Options. For the avoidance of doubt, all or a portion of such Contingent
Options will be vested and will become exercisable pursuant to the above terms. The
Company will take or cause to be taken all requisite actions to ensure capital gains
treatment of the Personal Options under Section&nbsp;102 of the Israeli Income Tax Ordinance,
including establishing an Israeli subsidiary, adopting an Israeli option plan that complies
with said Section&nbsp;102, filing such plan with the Israel Tax Authority and retaining a
trustee.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It is understood that at the present time, in view of the Company&#146;s plans for raising
capital, the Company may not have sufficient authorized but unissued shares of common stock
necessary upon the exercise of the Options. The Company will take such action as may be
reasonable and practical, as promptly as practicable and in any event within 90&nbsp;days of the
Commencement Date, to increase the number of authorized but unissued shares of common stock
to provide for the shares needed to be issued upon the exercise of the Options (the
&#147;Capital Increase&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All shares underlying the options will be registered by the Company with the Securities
and Exchange Commission on Form S-8 within 15&nbsp;days following the effective date of the
Capital Increase.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Notwithstanding the foregoing, in no event will you be permitted to hold securities
representing more than 9.9% of the Company&#146;s capital stock on an &#147;equal diluted&#148; basis.</TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">For purposes of this agreement, the following capitalized terms that have the following respective
meanings:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#147;Cause&#148; shall mean any of the following: (i)&nbsp;willful misconduct in the performance of your material
duties; (ii)&nbsp;participation in any fraud against the Company; (iii)&nbsp;conviction of, or a plea of
&#147;guilty&#148; or &#147;no contest&#148; to, a felony or any crime involving dishonesty; or (iv)&nbsp;intentional damage
to any property of the Company of material value.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#147;Change of Control&#148; shall mean the occurrence of any of the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(a)&nbsp;any &#147;person,&#148; as such term is currently used in Section 13(d) of the Securities Exchange Act of
1934, as amended (the &#147;1934 Act&#148;) (a &#147;person&#148;), other than Dr.&nbsp;David Sidransky, becomes a
&#147;beneficial owner&#148; (as such term is currently used in Rule&nbsp;13d-3 promulgated under the 1934 Act (a
&#147;Beneficial Owner&#148;) of 30% or more of the Voting Stock (as defined below) of the Company;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(b)&nbsp;the Board of Directors of the Company adopts any plan of liquidation providing for the
distribution of all or substantially all of the Company&#146;s assets;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(c)&nbsp;all or substantially all of the assets or business of the Company are disposed of in any one or
more transactions pursuant to a sale, merger, consolidation or other transaction (unless the
shareholders of the Company immediately prior to such sale, merger, consolidation or other
transaction beneficially own, directly or indirectly, in substantially the same proportion as they
owned the Voting Stock of the Company, more than fifty percent (50%) of the Voting Stock or other
ownership interests of the entity or entities, if any, that succeed to the business of the
Company);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(d)&nbsp;the Company combines with another company and is the surviving corporation but, immediately
after the combination, the shareholders of the Company immediately prior to the combination hold,
directly or indirectly, fifty percent (50%) or less of the Voting Stock of the combined company; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(e)&nbsp;Continuing Directors cease to constitute at least a majority of the Board of Directors of the
Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#147;Voting Stock&#148; of any entity shall mean the issued and outstanding share capital or other
securities of any class or classes having general voting power under ordinary circumstances, in the
absence of contingencies, to elect the members of the board of directors (or members of a similar
managerial body if such entity has no board of directors) of such entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#147;Continuing Director&#148; means a director who either was a director of the Company on the Commencement
Date or who became a director of the Company subsequent thereto and whose election, or nomination
for election by the Company&#146;s shareholders, was approved by a majority of the Continuing Directors
then on the Board of Directors of the Company.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>c07441exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><U><B>Exhibit&nbsp;99.1</B></U>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 10pt">Champions Biotechnology, Inc.
</DIV>


<DIV align="Center" style="font-size: 16pt; margin-top: 10pt">NEWS
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 10pt">855 N. Wolfe Street, Suite&nbsp;619, Baltimore, Maryland 21205 USA.<BR>
Tel. 410-369-0365
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">For Immediate Release
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Champions Biotechnology Reports Additions to its Management Team</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B>Baltimore, MD, October&nbsp;28, 2010 </B> &#151; Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a
company engaged in the development of advanced preclinical platforms and tumor specific data to
enhance the value of oncology drugs, today announced that Mr.&nbsp;Joel Ackerman has joined the
management team as the Chief Executive Officer of the Company. In addition, the Company announced
that Dr.&nbsp;Ronnie Morris will join the management team as President of the Company; Dr.&nbsp;Morris will
concentrate on the development and growth of the personalized medicine business, particularly the
Company&#146;s Personalized Oncology Services. Both Mr.&nbsp;Ackerman and Dr.&nbsp;Morris will join the company&#146;s
Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Mr.&nbsp;Ackerman spent 15&nbsp;years at Warburg Pincus, a leading private equity investment firm, from
1993 to 2008. While at Warburg Pincus, he was a partner of the firm, a member of the executive
management group and ran the healthcare services group. He invested in start-ups and early-stage
companies as well as later stage growth investments and management-led buyouts. For most of these
companies, Mr.&nbsp;Ackerman served on the board of directors and worked closely with the respective
management teams on strategy, financing, M&#038;A and organizational development. Currently, Mr.
Ackerman sits on the board of directors of Coventry Health Care, a publicly traded managed care
company, and Kindred Healthcare, a publicly traded company that owns hospitals and nursing homes.
He is also Chairman of the Board of One Acre Fund, a non-profit microfinance organization in
Western Kenya. He received a BA in physics from Columbia University and an MA in physics from
Harvard University.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Ronnie Morris, M.D. was most recently one of the founders of MDVIP, the national leader in
personalized healthcare. Serving as a board member, medical director<B><I>, </I></B>and part of the executive
management team, Dr.&nbsp;Morris helped build and manage MDVIP, a company that grew to a network of 400
doctors within 29 states servicing 125,000 consumers/patients. In December&nbsp;2009, MDVIP was
acquired by the Procter and Gamble Co. (NYSE:PG). Prior to MDVIP, Dr.&nbsp;Morris was the Chief Medical Officer and Executive V.P. of
AllianceCare, a 1500&#043; employee company that provided home healthcare, physical therapy and doctor
visits for home bound patients. At AllianceCare Dr.&nbsp;Morris developed and operated the physician
house call division of the business, and he was the general medical director for the company. He
is currently on the board of directors of APOS therapy. He was the managing partner of a large
multispecialty group that was acquired in 1998 by Promedco. Dr.&nbsp;Morris is a board certified
internist and up until 2004 he had a private practice in Boca Raton, Florida. He has been a
consultant for many pharmaceutical companies including Pfizer, Merck, and AstraZeneca.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Dr.&nbsp;David Sidransky, Chairman of the Board of the Company, said, &#147;We are all very excited
about Mr.&nbsp;Ackerman and Dr.&nbsp;Morris joining our team. They bring a highly successful track record
and years of valuable experience and empirical knowledge to help shape and grow our business.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Additional information regarding this announcement will be contained in a Form 8-K to be filed
by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>About Champions Biotechnology, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and
predictive tumor specific data to enhance and accelerate the value of oncology drugs. The
Company&#146;s Preclinical Platform is a novel approach based upon the implantation of primary human
tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk
Tumorgrafts&#153;) in a manner that preserves the biological characteristics of the original human
tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their
response to drugs is more predictive of clinical outcomes in cancer patients.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to
develop a portfolio of novel
therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of
development, the Company plans to sell, partner or license them to pharmaceutical and/or
biotechnology companies, as appropriate. The Company also offers its predictive preclinical
platform and tumor specific data to physicians for personalized patient care and to Companies for
evaluation of oncology drugs and drug candidates in models that integrate prognostic testing with
biomarker discovery.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating
development and valuation of oncology drugs, and advancing personalized treatment with a goal to
improve the lives of cancer patients globally.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>This press release contains &#147;forward-looking statements&#148; (within the meaning of the Private
Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions
Biotechnology generally uses words such as &#147;believe,&#148; &#147;may,&#148; &#147;could,&#148; &#147;will,&#148; &#147;intend,&#148; &#147;expect,&#148;
&#147;anticipate,&#148; &#147;plan,&#148; and similar expressions to identify forward-looking statements. One should
not place undue reliance on these forward-looking statements. The Company&#146;s actual results could
differ materially from those anticipated in the forward-looking statements for many unforeseen
factors. See Champions Biotechnology&#146;s Form&nbsp;10-K for the fiscal year ended April&nbsp;30, 2010 for a
discussion of such risks, uncertainties and other factors. Although the Company believes the
expectations reflected in the forward-looking statements are reasonable, they relate only to events
as of the date on which the statements are made, and Champions Biotechnology&#146;s future results,
levels of activity, performance or achievements may not meet these expectations. The Company does
not intend to update any of the forward-looking statements after the date of this press release to
conform these statements to actual results or to changes in Champions Biotechnology&#146;s expectations,
except as required by law.</I>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE: www.championsbiotechnology.com</B>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
